- Home
- GOOD vs ZYME Comparison
GOOD vs ZYME Comparison
Compare GOOD & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOOD
- ZYME
- Stock Information
- Founded
- GOOD 2003
- ZYME 2003
- Country
- GOOD United States
- ZYME United States
- Employees
- GOOD N/A
- ZYME N/A
- Industry
- GOOD Real Estate Investment Trusts
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- GOOD Real Estate
- ZYME Health Care
- Exchange
- GOOD Nasdaq
- ZYME Nasdaq
- Market Cap
- GOOD 673.3M
- ZYME 751.6M
- IPO Year
- GOOD N/A
- ZYME 2017
- Fundamental
- Price
- GOOD $17.03
- ZYME $13.68
- Analyst Decision
- GOOD Buy
- ZYME Buy
- Analyst Count
- GOOD 2
- ZYME 5
- Target Price
- GOOD $15.25
- ZYME $19.00
- AVG Volume (30 Days)
- GOOD 248.5K
- ZYME 581.1K
- Earning Date
- GOOD 11-04-2024
- ZYME 10-31-2024
- Dividend Yield
- GOOD 7.07%
- ZYME N/A
- EPS Growth
- GOOD N/A
- ZYME N/A
- EPS
- GOOD 0.21
- ZYME N/A
- Revenue
- GOOD $147,922,000.00
- ZYME $62,199,000.00
- Revenue This Year
- GOOD N/A
- ZYME $30.09
- Revenue Next Year
- GOOD $1.91
- ZYME N/A
- P/E Ratio
- GOOD $81.61
- ZYME N/A
- Revenue Growth
- GOOD N/A
- ZYME N/A
- 52 Week Low
- GOOD $11.89
- ZYME $7.97
- 52 Week High
- GOOD $17.53
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- GOOD 58.43
- ZYME 41.35
- Support Level
- GOOD $16.54
- ZYME $12.39
- Resistance Level
- GOOD $17.24
- ZYME $17.70
- Average True Range (ATR)
- GOOD 0.43
- ZYME 0.88
- MACD
- GOOD -0.00
- ZYME -0.31
- Stochastic Oscillator
- GOOD 73.96
- ZYME 11.26
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.